CURRICULUM VITAE

I.

a	Name	Olayinka Adejoke Kotila (nee Odunsi)	
b	Date of birth	3 August, 1975	
c	Department	Pharmaceutical Chemistry	
d	Faculty	Pharmacy	
e	College	Not Applicable	

II.

a	First Academic Appointment	Lecturer II	21 April, 2008
b	Present Post (with date)	Lecturer I	01 Oct., 2014

III. University Education (with dates)

a	University of Ibadan, Ibadan	1993 - 1999
b	University of Ibadan, Ibadan	2004 - 2006

IV. Academic Qualifications (with dates and granting bodies)

a	Bachelor of Pharmacy (B. Pharm), University of Ibadan	Feb. 1999
b	M.Sc. (Pharmaceutical Chemistry), University of Ibadan	Nov. 2006

V. Professional Qualifications and Diplomas (with dates)

a	Registered Pharmacist - Pharmaceutical Society of Nigeria (MPSN)	Feb., 1999
b	Certificate of Attendance of Genomic Epidemiology In Africa, Blantyre, Malawi	6-11 May, 2012
c	Certificate of Completion on Biomedical Informatics, University of Ibadan, Nigeria	20-22 Aug., 2012
d	Certificate of Attendance of Training on Mentorship (jointly organised by MEPIN and Northwestern University, Chicago, USA)	27-29 Aug., 2012
e	Certificate of Participation in CIPZ Workshop on Principles and Application of PCR Techniques, Ibadan, Nigeria	10-14 June, 2013
f	Certificate of Completion on Data Analysis and	7-14 July, 2013

Manuscript Writing Workshop, University of Ibadan, Nigeria

g Certificate of Completion of Pharmacometrics Course, Dar es Salaam, Tanzania — 5-8 Aug., 2013

h Certificate of Completion of Diagnostic Molecular Pathology Workshop, University of Ibadan, Nigeria — 14-17 April, 2014

VI. Scholarships, Fellowships and Awards (with date)

1.	MacArthur Foundation Multidisciplinary Research Grant (Co-Investigator)	Oct. 2009
2.	NIH Training award on Clinical Research, University of Ibadan, Nigeria	2010
3.	Global Health Initiative Fellowship Award, University of Chicago, USA	2010 & 2011 (twice)
4.	Wellcome Trust Bursary Award	2012
5.	MEPIN Year 02 Seed Award (Award number R24TW008878 from the Fogarty International Center)	2012
6.	NIH D43 Re-entry Grant Award	2013
7.	Novartis Scholarship Award – Pharmacometrics Course in Tanzania	2013
8.	Tertiary Education Trust Fund (TETFUND)	2014

VII. Honours, Distinctions and Membership of Learned Societies

Member, Pharmaceutical Society of Nigeria (MPSN)
Member, Nigerian Association of Pharmacists in Academia (NAPA)
Member, International Society for Study of Xenobiotics (ISSX).

VIII. Details of Teaching/Work Experience

a) Courses taught at undergraduate level:

2012-2013 Session	I taught across 300 to 500 level students and had the following contact hours in the specified courses taken.
	For 300 level courses, in PCH 301, I had eleven (11) contact hours; PCH 302, three (3) contact

	hours; PCH 303, eight (8) contact hours For 400 level courses, I undertook six (6) hours of teaching in PCH 402 and For 500 level course, in PCH 502, I had six (6) contact hours and forty-five (45) practical hours in PCH 501
2013-2014 Session	My teaching hours were in 300 level and 400 level classes and practical training in 500 level. For 300 level courses, in PCH 301, I had eleven (11) contact hours; PCH 303, eight (8) contact hours For 400 level courses, in PCH 402, I had twelve (12) contact hours For 500 level, I had forty-five (45) practical hours.
2014-2015 Session	My teaching hours were in 300 level and 400 level classes and practical training in 500 level. For 300 level courses, in PCH 301, I had eleven (11) contact hours; PCH 303, eight (8) contact hours For 400 level courses, in PCH 402, I had twelve (12) contact hours For 500 level, I had forty-five (45) practical hours.
2015-2016 Session	My teaching hours will be in 300 level and 400 level classes and practical training in 500 level. For 300 level courses, in PCH 301, I will have eleven (11) contact hours; PCH 303, eight (8) contact hours For 400 level courses, in PCH 402, I will have twelve (12) contact hours For 500 level, I will hold forty-five (45) practical hours.

b) <u>Undergraduate project supervision</u>

(i) Co-supervision - 2

(ii) Sole supervision - 5

c) Administrative experience

i.	Rapporteur, UI @ 60 Exhibition	2008
ii.	Member, Induction committee	2008 – 2014
iii.	Member, Computer committee	2010 till date
iv.	Member, CDDDP Implementation committee	2011 till date
v.	Departmental Class Co-ordinator for 500 Level	2012 till date
vi.	Member, Faculty Alumni Executive Committee	2013 till date
vii.	Member, Faculty Dress Code Committee	2013 till date

IX. Research

(a) Completed Research

- Spectrophotometric analysis of Lumefantrine-Chloranilic acid charge-transfer complex. (**See Publication 2**)
- Determination of physicochemical properties of Lumefantrine. (**See Publication 7**)
- Simultaneous spectrophotometric analysis of trimethoprim and sulphamethoxazole via charge-transfer complexation reaction with chloranilic acid. (**See Publication 10**)
- Epidemiological survey on hypersensitivity to sulphonamides in over a thousand (>1,000) respondents. **(See Publication 11)**
- Genotyping of the N-acetyltransferase enzyme 2 (NAT2) in over five hundred (>500) Nigerians including one hundred (100) HIV-positive patients.

(b) Research in progress

- Phenotype analysis of NAT2 in over three hundred (>300) Nigerian volunteers using two probe drugs: dapsone and caffeine
- Pharmacokinetics of dapsone, a NAT2 substrate drug in Nigerians.

My research work on N-acetyltransferase enzyme 2 (NAT2) phenotype analysis is sequel to the completion of NAT2 genotyping in Nigerians. The aim of the study is to investigate the degree of correlation between NAT2 genotype and phenotype. Drug-induced adverse reactions to substrates of NAT2 metabolism have been documented to be majorly influenced by individuals' genetic dispositions to it with the culprit gene being NAT2. Those who are slow/poor acetylators are prime victims of this clinical condition. Currently, data on NAT2 genotype-phenotype association for African populations, especially Nigeria, is scarce.

For this study, laboratory analysis involves use of chromatographic techniques and data analysis will involve use of pharmacokinetics computational software, NONMEM. It is expected that outcomes of this research will translate into real-time genetic data of NAT2 gene in Nigerians; better treatment outcomes and review of the national policy relating to use of substrate drugs of NAT2 such as sulphonamides, dapsone, hydralazine, isoniazid and procainamide.

X. Publications

Articles that have already appeared in Learned Journals

1. Babalola C.P, Olori E.O, **Kotila O.A**, Falade O, Kolade Y.T, Sylva B.O. (2009): Effect of Artesunate on the Urinary Excretion of Cloxacillin in Healthy Subjects. Nigerian Journal of Pharmaceutical Research Vol. 7 No.1, 29-36

2. Adegoke O.A, Babalola C.P, Isaac P.O.K, **Kotila O.A**. (2011): Spectrophotometric studies of the charge-transfer complexation between Lumenfantrine and Chloranilic acid in acetonitrile. Acta Pharmaceutica Sciencia Vol.53,135-149

3. Babalola C.P, Awoleye S.A, Akinyemi J.O, **Kotila O.A**. (2011): Evaluation of prescription pattern in Southwest Nigeria. Journal of Public Health and Epidemiology Vol. 3 No. 3, 94-98.

4. Babalola C.P, **Kotila O.A,** Dixon P.A.F, Oyewo A.E. (2011): Disposition of quinine and its major metabolite, 3-hydroxyquinine in patients with liver disease. Research in Pharmaceutical Biotechnology Vol .3 No.3, 25-29.

5. Babalola C.P, Ajayi O, **Kotila O.A,** Ameh S. (2011): In-Vitro Interaction Studies of Lumefantrine With Antacids**.** International Journal of Comprehensive Pharmacy. (IJCP) Vol. 3 No.1, 1-4

6. Babalola C.P, Kanu D.N, Okafor G.O, Wumi A, Ajayi O, **Kotila O.A**, Farombi E.O. (2013): Toxicological Effect of Sub-therapeutic, Therapeutic and Overdose Regimens of Halofantrine Hydrochloride on Male Albino Rats. Pharmacologia Vol. 4 No.3, 180-185

7. **Kotila O.A**, Olaniyi O, Adegoke O.A, Babalola C.P. (2013): Experimental Determination of the Physicochemical Properties of Lumefantrine. African Journal of Medicine and Medical Sciences Vol 42. No.3 , 209-214

8. Babalola C.P, Kolade Y.T, Adeyemo M.A, **Kotila O.A**, Ameh S.J, Adelakun T.A, Adewuyi S, Kwasi G.N, Scriba G.K. (2014): Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine. Global Journal of Medical research: B Pharma, Drug Discovery, Toxicology and Medicine. Vol 14. No1, 4-10

9. Babalola C.P, Oluwalana I, **Kotila O.A**, Adegoke O.A, Kolade Y.T, Ameh S.J. (2014). A Novel Derivatization Ultraviolet Spectrophotometric Method for the Determination of Dihydroartemisinin using *p*-Nitroaniline. Tropical Journal of Pharmaceutical Research Vol. 13 No.1, 127-133.

10. Adegoke O.A, Babalola C.P, **Kotila O.A**, Oyakhire O. (May, 2014):

Simultaneous Spectrophotometric Determination of Trimethoprim and Sulphamethoxazole following Charge-transfer Complexation with Chloranilic acid. Arabian Journal of Chemistry. *In press*

11. Akpan M.R, **Kotila O.A**, Akpa O.M, Fawole O, Falusi A.G, Babalola C.P. (2015). Self-reported Sulphonamide Hypersensitivity Reactions in Adults Living in Ibadan, Nigeria: A Cross-sectional Community-based Study. Nigerian Medical Journal Vol. 56 No 6, 404-410

XI. Major Conferences Attended with Papers Read (in the last 5 years)

July, 2012	3rd Unibadan Conference of Biomedical Research, University of Ibadan, Ibadan, Oyo State **Paper presented:** Genotype analysis of NAT2 gene in HIV-positive Nigerians
Nov., 2013	86th National Conference of the Pharmaceutical Society of Nigeria, Ilorin, Kwara State **Paper presented:** Self-reported adverse reactions to sulphonamides in Ibadan, Oyo State, Nigeria.
Aug., 2015	13th National Scientific Conference of Nigeria Association of Pharmacists in Academia (NAPA), Ibadan, Oyo State **Paper presented:** N-acetyltransferase II enzyme haplotyping in HIV-positive and healthy Nigerians and its relatedness to sulphonamide hypersensitivity

Signed
OLAYINKA A. KOTILA